The research of Dr. Sévigny’s team focusses on the functions of extracellular nucleotides, exerted through the activation of P2 receptors, with an emphasis on the enzymes that regulate their concentrations at the cell surface.  Dr. Sévigny and his team have also identified, cloned and characterized six new genes, including the first member of a new family encoding enzymes called NTPDases.  His team is interested in several biological functions including the regulation of inflammation in response to pathogenic determinants, the migration of immune cells, the functions of leukocytes, the contraction of smooth muscles, and in particular the regulation of inflammation of the intestine with an emphasis on epithelial cells and on a potential treatment for inflammatory bowel disease.

Dr Sévigny’s team uses animal models with KO mice as well as methods of cell biology (murine and human primary cells), pharmacology, biochemistry and immunology.

CHUL
2705, boulevard Laurier
T1-49
Québec, Québec
Canada G1V 4G2
293 entries « 1 of 30 »

Lopez V, Schuh HJM, Mirza S, Vaaßen VJ, Schmidt MS, Sylvester K, Idris RM, Renn C, Schäkel L, Pelletier J, Sévigny J, Naggi A, Scheffler B, Lee SY, Bendas G, Müller CE

Heparins are potent inhibitors of ectonucleotide pyrophosphatase/phospho-diesterase-1 (NPP1) - a promising target for the immunotherapy of cancer

Journal Article

Front Immunol, 14 , 2023.

Abstract | Links:

Zaigham ZH, Ullah S, Pelletier J, Sévigny J, Iqbal J, Hassan A

Synthesis and biological evaluation of sulfamoyl benzamide derivatives as selective inhibitors for h-NTPDases

Journal Article

RSC Adv, 13 (30), 2023.

Abstract | Links:

Rubenich DS, de Souza PO, Omizzollo N, Aubin MR, Basso PJ, Silva LM, da Silva EM, Teixeira FC, Gentil GFS, Domagalski JL, Cunha MT, Gadelha KA, Diel LF, Gelsleichter NE, Rubenich AS, Lenz GS, de Abreu AM, Kroeff GM, Paz AH, Visioli F, Lamers ML, Wink MR, Worm PV, Araújo AB, Sévigny J, Câmara NOS, Ludwig N, Braganhol E

Tumor-neutrophil crosstalk promotes in vitro and in vivo glioblastoma progression

Journal Article

Front Immunol, 14 , 2023.

Abstract | Links:

Zaman G, Ullah S, Uzair M, Batool S, Ahmad H, Ullah F, Pelletier J, Sévigny J, Iqbal J, Hassan A

Synthesis of Thieno[3,2-d]pyrimidine Derivatives through Sequential SN Ar and Suzuki Reactions as Selective h-NTPDase Inhibitors

Journal Article

ChemMedChem, 18 (14), 2023.

Abstract | Links:

Huang X, Gu W, Zhang J, Lan Y, Colarusso JL, Li S, Pertl C, Lu J, Kim H, Zhu J, Breault DT, Sévigny J, Zhou Q

Stomach-derived human insulin-secreting organoids restore glucose homeostasis

Journal Article

Nat Cell Biol, 25 (5), 2023.

Abstract | Links:

Noronha-Matos JB, Pinto-Cardoso R, Bessa-Andrês C, Magalhães-Cardoso MT, Ferreirinha F, Costa MA, Marinhas J, Freitas R, Lemos R, Vilaça A, Oliveira A, Pelletier J, Sévigny J, Correia-de-Sá P

Silencing NTPDase3 activity rehabilitates the osteogenic commitment of post-menopausal stem cell bone progenitors

Journal Article

Stem Cell Res Ther, 14 (1), 2023.

Abstract | Links:

Bi C, Schäkel L, Mirza S, Sylvester K, Pelletier J, Lee SY, Pillaiyar T, Sévigny J, Müller CE

Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39

Journal Article

Bioorg Chem, 135 , 2023.

Abstract | Links:

Younus HA, Saeed M, Mahmood A, Jadoon MSK, Hameed A, Asari A, Mohamad H, Pelletier J, Sévigny J, Iqbal J, Al-Rashida M

Exploring chromone sulfonamides and sulfonylhydrazones as highly selective ectonucleotidase inhibitors: Synthesis, biological evaluation and in silico study

Journal Article

Bioorg Chem, 134 , 2023.

Abstract | Links:

Naasani LIS, Sévigny J, Moulin VJ, Wink MR

UTP increases wound healing in the self assembled skin substitute (SASS)

Journal Article

J Cell Commun Signal, 17 (3), 2023.

Abstract | Links:

Naasani LIS, Azevedo JG, Sévigny J, Franco de Oliveira T, Maria-Engler SS, Wink MR

Epidermal melanocytes metabolize extracellular nucleotides by purinergic enzymes

Journal Article

Biochem Cell Biol, 101 (3), 2023.

Abstract | Links:

293 entries « 1 of 30 »
Signaler des ajouts ou des modifications

Active projects

  • A recombinant soluble NTPDase8 as a novel biological treatment for inflammatory bowel disease, from 2021-10-01 to 2026-09-30
  • Ectonucleotidases and Extracellular Nucleotides in Smooth Muscle Cell Contraction, from 2023-04-01 to 2028-03-31
  • Novel P2Y6 antagonists as a potential therapy for inflammatory bowel disease, from 2021-07-01 to 2025-06-30
  • Scaling up the production of recombinant human NTPDase8 in CHO expression system for in vivo testing, from 2023-09-01 to 2024-03-31

Recently finished projects

  • A novel approach to treating inflammatory bowel diseases through the blocking of P2Y6 receptors, from 2018-04-01 to 2023-03-31
  • Role of NTPDase1 and Extracellular Nucleotides in Smooth Muscle Cell Contraction., from 2016-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery